Kornimate/medical-research-clean huggingface dataset:
study to reveal if fibrinogen treatment effects blood clotting better than a platelet transfusion

Conditions: Blood Platelet Transfusion; Blood Clotting

Summary: patients with need of platelet transfusion for any reason will participate in this study. directly before the start of infusion and one hour after the end of platelet transfusion blood samples will be drawn and treated with different concentrations of fibrinogen (a blood clotting factor) in-vitro. blood samples with and without fibrinogen/platelet transfusion will be compared. the study hypothesis is that treatment with fibrinogen results in a better stabilisation of blood coagulation.

in total 300 patients with the need of platelet transfusion for whatever reason will be included when meeting the inclusion- and exclusion criteria. for all patients three visits are planned, where blood samples will be taken. the first blood samples will be taken directly before the start of platelet transfusion, the second 1 hour after the end of the platelet transfusion and the third after 24 hours. untreated citrate and edta blood samples from visit 1 will be serving as baseline for the coagulation testing. further citrate blood samples from the first visit will be spiked with different concentrations of fibrinogen in vitro. untreated citrate and edta blood samples will be taken 1 hour and 24 hours after platelet transfusion for comparison. further citrate blood samples will be spiked with different concentrations of fibrinogen in vitro again 1 hour after platelet transfusion. in addition, randomly chosen samples will be analyzed using confocal microscopy. routine coagulation analysis include activated partial thromboplastin time (aptt), prothrombin time(pt), fibrinogen, blood coagulation factor thirteen (fxiii), thromboelastometry (extem \& fibtem) before and after platelet transfusion.

Eligibility criteria:
inclusion criteria: * patient with the clinical need for platelet transfusion * age: 18 - 85 years exclusion criteria: * pregnant or nursing women * patients who disagree to participate in the study * for emergency patients: patients with known refusal of a participation in this clinical trial * active participation in a clinical trial * any condition, including the presence of laboratory abnormalities, which would place confound in the ability to interpret data from the study * any serious medical condition, laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the informed consent form

Keywords: platelet transfusion fibrinogen blood coagulation thrombocytopenia in-vitro experiments fgtw fit2012 factor i fibrin
remote care for cied patients in korea

Conditions: Arrhythmias, Cardiac

Summary: this trial is for monitoring the quality and satisfaction of cied patients who are naive with remote device monitoring.

patient satisfaction (using questionnaire) before and after wireless/wired monitoring and outpatient treatment time, variables in heart transplantation devices for wireless/wired monitoring, presence of heart failure, cardiovascular events such as arrhythmia, myocardial infarction or cerebral infarction, thromboembolism and admission related to cardiovascular cause. the questionnaire was adopted and modified from modified korean version of homasq (by youmi hwang,2021 from homasq; europace (2010))

Eligibility criteria:
inclusion criteria: 1. patients with biotronic cied implanted in st. vincent's hospital, catholic university of korea, republic of korea 2. patients who are literate and have perceptibility on questionnaire 3. patients who followed up more than 6 months after cied implantation 4. patients with age of \>20 years exclusion criteria: 1. patients with \ 6 months 2. illiterate patients or inapprehensive of questionnaire 3. patients with life expectancy of \<1 year

Keywords: pacemaker implantable cardioverter defbrillator cardiac resynchronization therapy
the role of methycobalamin in early dementia patients with vitamin b12 deficiency and hyperhomocysteinaemia.

Conditions: Dementia With Vitamin B12 Deficiency

Summary: patients who fit the inclusion criteria are admitted into the study. they are given 3 iv injection of mbl in the first week and one tablet three times a day for 16 weeks.


Eligibility criteria:
inclusion: * patients with dementia * serum b12 \< 200 pmol/l * serum homocysteine level \> 11.0 micro mol/l exclusion: significant communication problems * deafness, dysarthria, dysphasia etc. * unstable dm or hypertension * alcohol abuse * co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure * folate \< 10 g/dl * haemoglobin concentration \< 10g/d * abnormal thyroid function test or vdrl
comparative study for incidence of proximal junctional kyphosis between parathyroid hormone and denosumab following adult spinal deformity surgery : a prospective, randomized controlled trial

Conditions: Spine Deformity

Summary: medical therapy that can lower pjk rates are also being sought. teriparatide (tp), a recombinant human parathyroid hormone (pth 1-34), is a bone forming agent mainly used to treat osteoporotic patients with high risk of osteoporotic fracture. there has been reports suggesting protective effect of prophylactic tp to osteoporotic patients receiving asd surgery concerning pjk.6 although it had limitations of small sample size and surgical selection bias owing to study design being retrospective. we hypothesized prophylactic tp would act as to reduce the incidence of pjk and therefore reduce pjf and necessity of revision surgeries in patients after asd correction surgery. our study can consolidate the beneficial effect of prophylactic tp to patients receiving asd surgery by reducing the incidence of pjk.


Eligibility criteria:
inclusion criteria: 1. female patients between 50 years to 80 years of age with asd 2. multilevel instrumented fusion 3. cobb angle above 25̊ in coronal plane deformities, lumbar lordosis below 20̊ in sagittal plane deformities 4. minimum follow-up of 1 years exclusion criteria: 1. diagnosis being tumor or infectious condition like tb spondylitis were excluded 2. patients with adverse reactions or contraindications to tp were excluded; side effects to tp or bone cancer or metastasis
direct access physiotherapy in the pediatric emergency department

Conditions: Musculoskeletal Pain; Musculoskeletal Diseases or Conditions

Summary: the goal of this clinical trial is to compare two methods of managing low acuity musculoskeletal complaints in children and adolescents ages 6 to 17.99 years in the pediatric emergency department. the main question it aims to answer is whether delivering care in two methods is feasible. participants will receive care while in the emergency department and will be followed for a period of 1-month post-presentation.


Eligibility criteria:
inclusion criteria: * aged 6.00-17.99 years of age * present to the montreal children's hospital emergency department with a suspected msk complaint, traumatic or not * are given a triage score of 3 (urgent), 4 (less urgent), or 5 (nonurgent) according to the canadian triage and acuity scale (ctas) * are able to communicate in french or english exclusion criteria: * present with a major msk condition requiring urgent care (e.g., open fracture, open wound) * a red flag (e.g. progressive neurological disorder, infectious symptoms) * a co-morbid unstable condition.
prospective randomized comparison of transurethral resection by mean of white light and narrow band imaging

Conditions: Non Muscle Invasive Bladder Cancer

Summary: to date, fluorescence and narrow band imaging cystoscopy have been tested in many prospective within patient trials but only as an "add on" procedure. this results in a bias that does not allow to determine the real impact of such innovative technologies on bladder cancer management. hereby we propose the first prospective randomized trial which compares narrow band imaging trans urethral resection as a stand alone procedure versus white light transurethral resection. the primary end point is to assess the recurrence rate of bladder cancer lesions with each treatment modality. the study is designed to disclose an inferior recurrence rate (estimated 10%) in the group treated by narrow band imaging transurethral resection respect to the control group, treated by standard transurethral resection.


Eligibility criteria:
inclusion criteria: * all patients must be older than 18 years of age and female patients who are pregnant, breast feeding or not on adequate contraceptive measures will be excluded. * all patients will provide a written informed consent prior to the study. * consecutive patients from 2 centers in liguria (national institute for cancer research - genova and centro urologico di eccellenza asl 1 - imperia) with overt or suspected non muscle invasive bladder cancer, including cis detected by mean of random biopsies or a positive urinary cytology, will be included in the study and randomized to 2 treatments a, b arms. exclusion criteria: * patients with muscle invasive bladder cancer will be excluded. * patients submitted to immediate radical cystectomy after transurethral resection, irrespective of the clinical stage, will be excluded.

Keywords: bladder cancer recurrence
effects of obstructive sleep apnea treatment by fixed cpap and by auto-cpap (somnosmart2)

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the main purpose of this study is to investigate if treatment of obstructive sleep apnea syndrome (osas) by continuous positive airway pressure (cpap) given by a traditional cpap device administering a fixed air pressure, or by one automatic cpap device ("somnosmart2", weinmann, hamburg) administering variable pressures, have different effects on sympathetic nervous system tone (as reflected by urinary excretion of norepinephrine and its catabolite normetanephrine) and on blood pressure.

a nocturnal home cardiorespiratory recording will performed for diagnosis of osa. during the same night, patients will be asked to collect their urines. twentyfour-hour ambulatory bp monitoring (abpm) will be performed starting from the next morning. after analysis of the polygraphic recording, subjects with ahi \<15 will be excluded from the study, while cpap will be proposed as a treatment to the other patients. before starting treatment, a full night standard polysomnography will be performed: in subjects assigned to fixed cpap for attended cpap titration; in the other subjects during application of the somnosmart2 device, to verify if obstructive events are adequately eliminated by it. after analysis of polysomnography, patients will be given a fixed cpap or the auto-cpap device for nocturnal home use. two months later, compliance to treatment will be verified measured by the in-built time counter of the devices. then, cardiorespiratory monitoring during application of the device used for treatment, nocturnal urine collection and 24-hour abpm will be repeated.

Eligibility criteria:
inclusion criteria: * obstructive sleep apnea syndrome deserving cpap treatment exclusion criteria: * current pharmacological treatment

Keywords: osas blood pressure sympathetic nervous system treatment cpap
assessment of risk factors and outcome of thrombocytopenia in icu patients

Conditions: Thrombocytopenia

Summary: the many comorbidities in the severely ill patient also make thrombocytopenia very common (∼ 40%) in intensive care unit patients. the risk of bleeding is high with severe thrombocytopenia and is enhanced in intensive care patients with mild or moderately low platelet counts when additional factors are present that interfere with normal hemostatic mechanisms (eg, platelet function defects, hyperfibrinolysis, invasive procedures, or catheters).

the many comorbidities in the severely ill patient also make thrombocytopenia very common (∼ 40%) in intensive care unit patients. the risk of bleeding is high with severe thrombocytopenia and is enhanced in intensive care patients with mild or moderately low platelet counts when additional factors are present that interfere with normal hemostatic mechanisms (eg, platelet function defects, hyperfibrinolysis, invasive procedures, or catheters). even if not associated with bleeding, low platelet counts often influence patient management and may prompt physicians to withhold or delay necessary invasive interventions, reduce the intensity of anticoagulation, order prophylactic platelet transfusion, or change anticoagulants due to fear of heparin-induced thrombocytopenia. the many comorbidities in the severely ill patient also affect platelet homeostasis, and, consequently, thrombocytopenia is very common in critically ill patients treated in the intensive care unit (icu). thrombocytopenia is usually defined as a platelet count of \< 150 × 109/l, whereas severe thrombocytopenia is considered as platelet counts \< 50 × 109/l. thrombocytopenia has six major mechanisms, and it can be induced by hemodilution, increased platelet consumption (both are very common in the icu after tissue trauma, bleeding, and disseminated intravascular coagulopathy \[dic\]), increased platelet destruction (ie, immune mechanisms), decreased platelet production, increased platelet sequestration, or by the laboratory artefact of pseudothrombocytopenia .

Eligibility criteria:
inclusion criteria: * children and infants aged one month to 18 years admitted to the icu in period from august 2023 to august 2024 and developed thrombocytopenia documented in laboratory investigation done in picu. exclusion criteria: * patients older than 18 years * patients diagnosed with congenital thrombocytopenia (tar syndrome...etc)
the indications and clinical efficacy of pelvic organ prolapse surgery

Conditions: Pelvic Organ Prolapse

Summary: one thousand patients with stage\>2 pop are recruited. the patients are all received surgeries,such as transvaginal synthetic mesh surgery, the sacral fixation, tissue repair surgery and colpocleisis. the patients with pop who have not undergone surgery are excluded. postoperatively, the investigators investigate the indications and clinical efficacy of pelvic organ prolapse surgery.

postoperatively, the investigators analyze the patients' subjective and objective recurrent rates. the investigators compare the quality of life by filling out the preoperative and postoperative scoring questionnaires (pisq 12, pfdi-20, pfiq-7).the electrical physiological changes will be focused on. the investigators also use overactive bladder symptom score(oabss) to assess the lower urinary tract symptoms.

Eligibility criteria:
inclusion criteria: * the patients with stage\>2 pop are recruited.the patients are all received surgeries, which include transvaginal synthetic mesh surgery, the sacral fixation, tissue repair surgery and colpocleisis. exclusion criteria: * the patients with pop who have not undergone surgery are excluded.

Keywords: pelvic organ prolapse
the role of quadratus lumborum blocks following minimally invasive hysterectomy

Conditions: Pain, Postoperative

Summary: the purpose of this study is to compare quality of recovery as well as peri-operative systemic opiates use and pain scores in patients undergoing laparoscopic or robotic hysterectomy when local anesthetic versus quadratus lumborum nerve block (ql-2) is added to the standard pain management.


Eligibility criteria:
inclusion criteria: * english or spanish speaking * american society of anesthesiologists (asa) physical status 1-3 * planned laparoscopic or robotic hysterectomy exclusion criteria: * history of chronic pain requiring preoperative opioids, known alcoholism disorder * congenital coagulopathy, * localized soft tissue infection, * use of anticoagulants, * dementia, inability or refusal to provide consent for the surgery * morbid obesity (bmi \> 50), due to expected technical difficulty to achieve the block

Keywords: laparoscopy hysterectomy
intraoperative celiac plexus neurolysis for patients with operable pancreatic and periampullary cancer

Conditions: Pancreatic Cancer

Summary: determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain

pancreatic adenocarcinoma is the fourth leading cause of cancer related death in the united states and is usually fatal. surgery provides the only chance for long-term survival. pain is a significant, often difficult to control component of survivorship for many who succumb to this disease. the purpose of this trial is to evaluate the effect of ethanol celiac plexus neurolysis (alcohol nerve block) in patients undergoing surgical intervention for pancreatic cancer. patients undergoing surgery for pancreatic cancer will be enrolled in a prospective randomized double blind placebo controlled clinical trial. this protocol is designed to definitively determine the role of ethanol celiac plexus neurolysis as a simple addition to the surgical management of pancreatic adenocarcinoma and help define the standard of care for cancer associated pain management in this disease.

Eligibility criteria:
inclusion criteria: * preoperative imaging indicates possibility of resectable pancreatic cancer * intraoperative biopsy histologically confirming pancreatic adenocarcinoma exclusion criteria: -

Keywords: pancreatic cancer periampullary cancer resectable unresectable celiac plexus neurolysis surgery
bioavailability of oxymorphone hydrochloride 40 mg extended release tablets under fasted conditions

Conditions: Pain

Summary: the purpose of this study is to demonstrate the relative bioequivalence of oxymorphone hydrochloride extended-release tablets (sandoz) with opana extended release oxymorphone hydrochloride tablets.

bioequivalence based on fda criteria.

Eligibility criteria:
inclusion criteria: * no clinically significant abnormal findings on physical exam, medical history or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c * treatment for drug or alcohol dependence
a study of pentamidine plus dapsone in the prevention of pneumocystis carinii pneumonia (pcp) in hiv-infected patients who cannot take trimethoprim or sulfonamides

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to compare the safety and efficacy of aerosolized pentamidine and dapsone in the prevention of pneumocystis carinii pneumonia (pcp) in high-risk hiv-infected patients who are intolerant to trimethoprim and/or sulfonamides. both aerosolized pentamidine and dapsone have been shown to prevent pcp, but both drugs cause side effects. this study attempts to determine which drug is more efficacious as prophylaxis against pcp in patients who cannot tolerate trimethoprim/sulfamethoxazole.

both aerosolized pentamidine and dapsone have been shown to prevent pcp, but both drugs cause side effects. this study attempts to determine which drug is more efficacious as prophylaxis against pcp in patients who cannot tolerate trimethoprim/sulfamethoxazole. patients are evenly divided between two treatment arms to receive either aerosolized pentamidine every 4 weeks or dapsone orally three times weekly. follow-up data is collected every 3 months, and patients are clinically evaluated every 6 months. patients who develop pcp or a severe or persistent study drug toxicity may be switched to the alternative study drug at the clinician's discretion. average duration of follow-up is 2 years.

Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * cd4 count \<= 200 cells/mm3 or \<= 15 percent of total lymphocytes or a history of prior pcp. * history of intolerance to trimethoprim and/or sulfonamides. * no active pneumocystosis. patient or guardian must sign informed consent. pregnant patients are eligible at the clinician's discretion. patients who do not meet required laboratory values may be eligible at the discretion of the clinician. exclusion criteria concurrent medication: excluded: * any medication with potential anti-pcp activity. patients with the following prior conditions are excluded: * treatment-limiting reaction to pentamidine or dapsone.

Keywords: pneumonia, pneumocystis carinii pentamidine dapsone acquired immunodeficiency syndrome aids-related complex
single-port lc might be preferable for managing ovarian dermoid cyst.

Conditions: Abdominal Pain; Ovarian Spillage; Endobag Rupture; Ovarian Reserve

Summary: minimally invasive surgery has become the standard treatment for many gynecologic disease processes. in the last decade, numerous studies have demonstrated that laparoscopic approaches to various gynecologic oncology conditions-particularly for early-stage endometrial and cervical cancers as well as select pelvic masses-is feasible and results in shorter hospital stays, improved quality of life and comparable surgical and oncologic outcomes to abdominal staging.for instance, the typical gynecologic robotic surgical procedure will require two to three 5-mm ports and one 12-mm laparoscopic ports. recently, an even less invasive alternative to conventional laparoscopy surgery has been developed: laparoendoscopic single-site surgery (less), also known as single-port surgery. single port laparoscopy is an attempt to further enhance the cosmetic benefits of minimally invasive surgery while minimizing the potential morbidity associated with multiple incisions. preliminary advances in less as applied to urologic and gastrointestinal surgery demonstrate that the techniques are feasible provided that both optimal surgical technical expertise with advanced skills and optimal instrumentation are available. recently, several publication showed the single port laparoscopic surgery is feasibility in gynecologic surgery including oophorectomy, cystecomty, and myomecomty. to our knowledge, the sample size of recent publication about single port surgery including cystectomy and myomecomty is small. furthermore, these studies lack the comparison of single port and convectional laparoscopic surgery. base on our recent study demonstrated that either the single-port or the conventional approach can be used for lavh, but the single-port lavh technique yielded less postoperative pain (chen et al., obestet gynecol, 2011). the purpose of this study was to assess the feasibility of single port laparoscopic surgery in the treatment of benign gynecologic disease.

this study was designed as a retrospective case-control study, and port placement was one of the differences in operative procedures between the two groups. patients with ovarian dermoid cysts were evaluated at taipei veterans general hospital from june 13, 2011 through june 12, 2013. approval for the study was obtained from the hospital's ethics committee, and informed consent was obtained from all patients (vghirb 2011-06-004ia).

Eligibility criteria:
inclusion criteria: * the patient received cystectomy for ovarian dermoid cysts (even while pregnant), the cyst received an american society of anesthesiologists physical status classification of i or ii, and the patient provided signed informed consent. exclusion criteria: * patients who received an oophorectomy for dermoid cyst or had a dermoid ovarian cyst with malignant potential and concomitant surgeries for uterine lesion, pelvic organ prolapse or urodynamic urinary incontinence were excluded.

Keywords: single-port laparoscopy abdominal pain ovarian spillage endobag rupture ovarian reserve